MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ANNX stock logo

ANNX

Annexon, Inc.

$5.07
0.08
 (1.5%)
Exchange:  NASDAQ
Market Cap:  829.862M
Shares Outstanding:  38.221M
Delayed data
Calculate ANNX Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Douglas E. Love
Full Time Employees:  92
Address: 
1400 Sierra Point Parkway
Brisbane
CA
94005
US
Website:  https://www.annexonbio.com
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company’s developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington’s disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/08/12 — Q2 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue000
Gross Profit0-3,454-3,686
EBITDA-132,089-134,746-204,040
Operating Income-143,723-154,073-216,407
Net Income-134,237-138,200-206,690

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets297,674350,071277,571
Total Liabilities47,11856,96665,923
Total Stockholders Equity250,556293,105211,648
Total Debt31,35528,97226,201
Cash and Cash Equivalents225,11049,498162,051

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-121,142-118,006-186,356
Capital Expenditure-193-15-137
Free Cash Flow-121,335-118,021-186,493
Net Income-134,237-138,200-206,690
Net Change in Cash85,090-175,612112,551

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)252,201.698Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)2,851,657.919Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)1,030,584.832Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)0Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)0Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)0Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)5,995.125Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)1,090,147.387Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)330,634.451Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)0Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)0Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)0Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)2.130Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)7.030Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.040Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)6Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)4Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
0  ?P/S
 (TTM)
: 
0
?Net Income
 (TTM)
: 
-134237000  ?P/E
 (TTM)
: 
-4.37
?Enterprise Value
 (TTM)
: 
656.063M  ?EV/FCF
 (TTM)
: 
-3.4
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-106.15%  ?ROIC
 (TTM)
: 
-99.93%
?Net Debt
 (TTM)
: 
-310509000  ?Debt/Equity
 (TTM)
: 
0.13
?P/B
 (TTM)
: 
5.48  ?Current Ratio
 (TTM)
: 
5.53

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about ANNX valuation

Is Annexon, Inc. (ANNX) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Annexon, Inc. (ANNX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ANNX a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ANNX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ANNX’s P/E ratio?

You can see ANNX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ANNX?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ANNX a good long-term investment?

Whether ANNX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ANNX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

1.5
MARKETSnap

Trading Metrics:

Open: 5   Previous Close: 4.99
Day Low: 4.92   Day High: 5.07
Year Low: 2.03   Year High: 7.18
Price Avg 50: 5.39   Price Avg 200: 5.32
Volume: 1.054M   Average Volume: 3.172M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
18-05-2026 16:05
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
12-08-2026 14:07
Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
12-08-2026 06:05
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
12-08-2026 06:00
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
Annexon: Perfect Complement To A Speculative Biotech Portfolio
14-07-2026 05:43
Annexon: Perfect Complement To A Speculative Biotech Portfolio
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
04-06-2026 03:07
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read